Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
2021 IM core margin increased to 36.2% (+130bps)
Innovative Medicines
Sandoz
Group
Q4 2021
FY 2021
Core operating
Net sales 1
change vs. PY
income2
change vs. PY
Core margin 2
Core margin²
change vs. PY
Net sales 1
change vs. PY
Core operating
income2
change vs. PY
Core margin²
Core margin²
change vs. PY
(in % cc)
(in % cc)
(%)
(%pts cc)
(in % cc)
(in % cc)
(%)
(%pts cc)
7
15
33.6
2.4
6
10
36.2
1.3
2
0
20.9
-0.4
-2
-14
21.4
-2.9
6
12
28.9
1.6
4
6
32.1
0.5
1. Q4 sales growth for Group, IM and Sandoz includes +1% point impact from a reclassification of contract manufacturing from other revenue to sales. Sandoz FY sales growth also benefited +1% point from this reclassification. 2. Constant
currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report.
42 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation